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Abstract
Background: Previous studies have explored the effect of granulocyte colony stimulating factor (G-CSF) administration
on the outcome of assisted reproductive technology (ART), and came into controversial conclusions. The present meta-
analysis aims to assess whether G-CSF administration has beneficial effect on the outcome after ART.
Method: The electronic databases Pubmed, Embase and Google Scholar were searched up to May 2016. Articles that
studied the effect of G-CSF administration on the outcome after ART were included in the present meta-analysis. Odds
ratio (OR) with 95 % confidence interval (95 % CI) were calculated to assess the effect of G-CSF administration on the
outcome after ART. The outcomes of interest were implantation rate (IR) and pregnancy rate (PR).
Results: Four cohort studies with 1101 embryos transplantation assessed the effect of G-CSF administration on IR and
6 studies with 621 cycles assessed the role of G-CSF administration in PR. Meta-analysis did not found an increased
embryo IR in G-CSF administration cycles [OR 1.59 (95 % CI 0.74–3.41). whereas the PR with G-CSF administration was
significantly higher compared with cases without G-CSF administration [OR 2.03 (95 % CI 1.19–3.46)]. Additionally, we
found that G-CSF administrated subcutaneously resulted in significantly higher PR [OR 3.12 (95 % CI 1.67–5.81)] and IR
[OR 2.82 (95 % CI 1.29–6.15)] compared with control group, whereas G-CSF administrated via local uterine infusion had
no beneficial effect on the PR [OR 1.42 (95 % CI 0.91–2.24)] and IR [OR 1.10 (95 % CI 0.76–1.60)] after ART.
Conclusions: G-CSF administration may have beneficial effect on clinical pregnancy outcome after ART. Subcutaneous
injection may be an optimal route of G-CSF administration. Further cohort studies are required to explore the mechanisms
undergone the effect and investigate the best route and dose of G-CSF administration.
Keywords: Granulocyte colony-stimulating factor (G-CSF), Implantation rate, Pregnancy rate, Assisted reproductive
technology (ART)
Background
Successful embryo implantation required good-quality
embryos and receptive endometrium. Studies indicated
that endometrial receptivity should responsible for 2/3
embryo implantation failure. As shown in our previous
papers, endometrial thickness is an important index
evaluating endometrial receptivity [1, 2]. And many
studies believed that endometrial thickness below a
threshold is associated with embryo implantation failure
and reduced pregnancy rate [3–8].
So far, many therapies have been attempt to enhance
the endometrial thickness and improve the endometrial
receptivity, such as extending estrogen administration
[9], low-dose aspirin [10], combination pentoxifylline
and tocopherol [11], vaginal sildenafil citrate [12], and
stem cells treatment [13, 14]. These treatments have im-
proved endometrial receptivity and increased implant-
ation and pregnancy rate in ART cycles in some extent.
However, many cases still remain unresponsive.
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Lately, granulocyte colony-stimulating factor (G-CSF)
has been used in the treatment of thin endometrium.
Five years ago, Gleicher et al applied G-CSF in 4 infertile
women with unresponsive thin endometrium for the
first time, and resulted in successful pregnancy [15].
Subsequently, several studies have explored the effect of
G-CSF administration on the outcome of ART with thin
endometrium [16–20], or with repeated IVF failure (RIF)
[21, 22]. And one study implied G-CSF in unselected
women who received in vitro fertilization (IVF) treatment
[23]. These studies came into controversial conclusions,
so both clinicians and infertile women are in an awkward
position of whether the G-CSF should be given.
In the present review, we aim to further evaluate
whether G-CSF administration has beneficial effect on
the outcome of ART with thin endometrium or with RIF
and perform a systematic review and meta-analysis of
the available literatures.
Methods
Identification of the literature
The electronic databases Pubmed, Embase and Google
Scholar were searched up to May 2016. We included
papers which explore the effect of G-CSF administration
on thin endometrium and/or clinical outcome after ART
treatment. The keywords were as follows: [(“G-CSF” or
“CSF” or “granulocyte-stimulating factor”) and (“thin
endometrium” or “endometrium receptivity” or “endo-
metrial receptivity” or “endometrium thickness”) and
(“in vitro fertilization” or “IVF” or “intracytoplasmic
sperm injection” or “ICSI” or “frozen embryo transfer”
or “FET” or “infertility treatment” or “assisted reproduct-
ive technology”)]. There were no limitations on the time
and the type of the publications.
Titles and abstracts of all identified studies were
screened and the full paper of the preselected articles
was reviewed by two researchers. A 2 × 2 table was ex-
tracted from the articles. Any discrepancies between the
two reviewers were resolved by group discussion.
Eligibility criteria
Cohort studies with control group and RCTs investigat-
ing the effect of G-CSF administration on the endomet-
rium and/or ART outcomes were considered to be
eligible for inclusion. Studies without control group were
excluded even if the content was related. Papers written
in non-English were excluded.
The patient population comprised infertile women
with all ages, receiving the IVF or intracytoplasmic
sperm injection (ICSI) or frozen embryo transfer (FET)
treatment. Cycles with donor oocyte/sperm and intra-
uterine abnormalities were excluded from analysis.
The main study outcomes were embryo implantation
rate (determined by the number of gestational sacs at
least 28 days after embryo transplantation based on the
total number of embryos transferred per group), clinical
pregnancy rate (gestational sac and fetal heart on ultra-
sound examination). All clinical outcomes were calcu-
lated per cycle.
Quality assessment
Each selected study was scored for their relevance and
methodological quality by using the Strengthening the
Reporting of Observational Studies in Epidemiology
(STROBE) checklists for Observational Studies. In
addition, some information, such as sample size, study
design, blinding, selection bias, information bias, attri-
tion bias, and the stimulation protocol used were taken
into consideration. Two reviewers completed the quality
assessment, and any disagreements about inclusion were
resolved by group discussion.
Statistical analysis
A standard meta-analytic method was utilized to com-
pare the studies which were included in this study and
Odds Ratio (OR) with its 95 % CI was applied to express
the combined result. Forest plots evaluated the hetero-
geneity of the studies graphically and l2 statistic quanti-
fied the heterogeneity between studies statistically. The
heterogeneity was considered as low when the value was
less than 50 % [24]. A random effect model or a fixed ef-
fect model was implied to evaluate a pooled OR and its
95 % CI. RevMan 5.0 was used to perform the statistical
analysis (Cochrane Collaboration, Oxford, UK). The
results were regard to be statistically significant when
the P value was <0.05.
Results
Studies selection and characteristics
The search strategy yielded 25 citations. 12 citations
were irrelevant and were excluded after reviewing the
titles and the abstracts. Of the 13 remaining publica-
tions, seven were excluded and the reasons were as fol-
lows: two studies were case reports, three studies were
reviews, and two studies were cohort studies without
control groups (Fig. 1).
At last, six eligible studies were included in the review
(two IVF studies, three FET studies, one IVF/FET study). All
included studies comprising 621 cycles showed the effect of
G-CSF administration on the pregnancy rate after ART with
172 pregnancies. Of these, 4 publications involved 1101 em-
bryos transplantation also reported implantation rate.
Table 1 listed the characteristics of the included studies.
Of these six studies, four studies were designed prospect-
ively, one was retrospective and one was retrospective / pro-
spective. Three of the papers evaluated the effect of G-CSF
administration on outcome of ART cycles with thin endo-
metrium, two of these studies assessed the influence of
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G-CSF administration on RIF, and one study investigated
the efficacy of G-CSF usage in routine, unselected IVF cy-
cles. G-CSF was administered subcutaneously in two studies
and by transcervical intrauterine infusion in four studies.
Meta-analysis
Six studies were included in the present review and meta-
analysis to evaluate the G-CSF’s effect on PR after ART.
We found a significant increased PR in infertile women
who received the G-CSF administration compared with
those without G-CSF. With a P value <0.1, the heterogen-
eity showed to be moderate without significance (l2 = 49 %,
P = 0.08). The pooled OR with a random effects model
was 2.03 (95 % CI 1.19–3.46, P = 0.010) (Fig. 2).
Of these studies, 4 also analyzed the effect of G-CSF
administration on implantation rate. The result of the
Fig. 1 Flow chart showing study selection process
Table 1 Characteristics of studies included in a systematic review and meta-analysis of G-CSF and pregnancy outcome after ART
Study Type of study Women Treatment Protocol Dose and Rout of
G-CSF administration
Outcome
2012 Scarpellini F RCT RIF IVF Not mentioned 300ug subcutaneously P




100ug uterine infusion I, P, M
2014 Eftekhar M Pro Thin endometrium FET extended estrogen
cycle
300ug uterine infusion Chemical P, P
2014 Barad DH RCT Unselected IVF/FET Not mentioned 300ug uterine infusion I, P
2015 Bin Xu Retro/Pro Thin endometrium FET Natural cycle/EMS 300ug uterine infusion I, P, M, B
2016 Aleyasin A RCT RIF IVF GnRH-a long protocol 300ug subcutaneously I, CP, P, EP
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meta-analysis indicated that there was similar implant-
ation rate between G-CSF group and control group. The
Q statistic P-value was below 0.05, indicating heterogen-
eity of the studies (l2 = 78 %, P = 0.003). The random
effects model was implied and the combined OR was
1.59 (95 % CI 0.74–3.41, P = 0.23) (Fig. 3).
In addition, we presented stratified results by the rea-
son of G-CSF administration (thin endometrium n = 3;
RIF n = 2; unselected women n = 1). As only one paper
was related to unselected infertile women, we analyzed
cycles with “thin endometrium” and “RIF”, separately.
When evaluating the effect of G-CSF administration on
PR, 3 studies were associated with thin endometrium
and 2 studies were with RIF. The results indicated that a
significant increased PR with G-CSF administration in
both thin endometrium cycles (OR 2.09; 95 % CI
1.14–3.82, P = 0.02) and RIF cycles (OR 3.12; 95 % CI
1.67–5.81, P = 0.0003) (Fig. 4).
When evaluating the IR in cycles with thin endomet-
rium or RIF, 2 studies were with thin endometrium and
only one study was with RIF. The result showed signifi-
cant increased implantation rate when G-CSF was ad-
ministrated in both thin endometrium cycles (OR 1.97;
95 % CI 1.14–3.42, P = 0.02) and the only one study
which assessed the IR in RIF cycles showed beneficial
effect of G-CSF administration on the embryo implant-
ation (Fig. 5).
Besides, we also carried out a subgroup analysis
according to the route of G-CSF administration (sub-
cutaneous injection n = 2; uterine infusion n = 4). When
evaluating the effect of G-CSF administration on PR,
two studies administrated G-CSF via subcutaneous
injection and four studies implied G-CSF by uterine in-
fusion. The results showed an increased PR when G-CSF
was administrated via subcutaneous injection (OR 3.12;
95 % CI 1.67–5.81, P = 0.003), and a similar PR when
G-CSF was given via uterine infusion (OR 1.43; 95 % CI
0.91–2.24, P = 0.12) (Fig. 6). When evaluating the IR in
cycles with different routes of G-CSF administration,
one study used G-CSF subcutaneously and three studies
applied G-CSF via uterine infusion. The result showed
that there was no difference in IR when G-CSF was ad-
ministrated via uterine infusion (OR 1.10; 95 % CI 0.76–
1.60, P = 0.62) and the only one study used G-CSF sub-
cutaneously showed an increased IR when G-CSF was
administrated (Fig. 7).
All of the included studies have got good marks when
the Newcastle-Ottawa Quality Assessment Scale was
used (not shown). The funnel plots of meta-analysis,
which evaluating the effect of G-CSF administration on
PR/IR, was symmetrical and suggested that there was no
publication bias (Additional file 1: Figure S1, Additional
file 2: Figure S3, Additional file 3: Figure S4, Additional
file 4: Figure S5 and Additional file 5: Figure S6). How-
ever, the studies showed modest publication bias when
assess the effect of G-CSF administration on embryo IR
(Additional file 6: Figure S2).
Discussion
For all we know, the present study is the first systematic
review and meta-analysis which assess the effect of
G-CSF administration on the PR and IR after ART.
Fig. 2 Forest plot showing the results of meta-analysis of studies evaluating the effect of G-CSF administration on pregnancy rate after ART
Fig. 3 Forest plot showing the results of meta-analysis of studies evaluating the effect of G-CSF administration on embryo implantation rate after ART
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Many studies have attempted to explore the role of G-CSF
administration in IVF / ICSI / FET treatment cycles. Sev-
eral studies found G-CSF administration have positive
effect on the outcome after ART [15, 16, 20–22], while
other studies did not show an improved outcome after
ART with G-CSF administration [17, 18, 23]. In the
present review and meta-analysis, 6 and 4 studies were in-
cluded to evaluate the effect of G-CSF administration on
the PR and IR, respectively.
The results have demonstrated that the G-CSF admin-
istration benefit the PR after ART cycles either with thin
endometrium or RIF. The pooled OR was 2.03 for PP
(95 % CI 1.19–3.46). IR showed an increased tendency
with OR 1.59 (95 % CI 0.74–3.41), and there was no
significantly difference between G-CSF group and non-
G-CSF group.
In general, an adequate endometrial thickness above a
threshold is necessary for embryo implantation. Thin
endometrium always leads to embryo implantation fail-
ure. Besides, many couples still remain unsuccessful
after several IVF attempts even if with normal endomet-
rial thickness. With the deepening of understanding, re-
searchers realized the important role of G-CSF in
reproduction [25–31].
Gleicher and his co-authors reported the successful
application of G-CSF in the treatment of thin endomet-
rium for the first time in 2012. This paper reported four
patients with thin endometrium conceived successfully
Fig. 4 Forest plots showing the results of meta-analysis of studies evaluating the effect of G-CSF administration on pregnancy rate after ART cycles with thin
endometrium or with RIF
Fig. 5 Forest plots showing the results of meta-analysis of studies evaluating the effect of G-CSF via different administration routes on pregnancy
rate after ART cycles
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after receiving G-CSF administration via uterine infu-
sion. Subsequently many cohort studies were carried out
to evaluate the effect of G-CSF administration on the
outcome of ART cycles with thin endometrium or RIF,
and came into controversial conclusions [15–18, 20–23].
It is well known that G-CSF, as a kind of cytokines,
could stimulate the hematopoietic progenitor cells to
proliferate and differentiate. And recently many re-
searchers have found that G-CSF is likely associated with
the reproductive system functions of females, for example
follicular development, ovulation, ovarian response to
stimulation, and establishment and maintenance of preg-
nancy [27, 32–36].
Most studies and our present meta-analysis demon-
strated that G-CSF administration have beneficial effect
on the clinical outcome after embryo transplantation.
The possible explanations for the beneficial effect of
G-CSF on the outcome of ART were as follows:
Firstly, G-CSF, which is a glycoprotein of growth factor
family, has been found to regulate endometrial growth,
and play a role in the genesis of early endometriotic
lesions [37]. Another study showed that G-CSF would
exert a direct effect on endometrial epithelial cell prolif-
eration [38]. Additionally, G-CSF may stimulate the
endometrial stem cells or mobilize bone marrow stem
cells, and improve the development of endometrium
[13, 20, 39]. To investigate the influence of G-CSF
administration on the proliferation and differentiation
of endometrial stromal cells, a study by Tanaka et al
[32] found that G-CSF administration could induce
the human endometrial stromal cells to be decidualization
via cAMP-mediation in both autocrine and paracrine
Fig. 6 Forest plots showing the results of meta-analysis of studies evaluating the effect of G-CSF administration on embryo implantation rate after
ART cycles with thin endometrium or with RIF
Fig. 7 Forest plots showing the results of meta-analysis of studies evaluating the effect of G-CSF via different administration routes on embryo implantation
rate after ART cycles
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ways. So the G-CSF could expand the endometrial thick-
ness and improve the endometrial receptivity.
Secondly, G-CSF and its receptor were expressed in
both the endometrium and the fetomaternal interface
[32, 40, 41]. Both fetal chorionic villous and maternal
decidual tissues could secrete G-CSF during the first tri-
mester. One study by Salmassi et al found infertile
women who become pregnant have an increased level of
serum G-CSF compared with women who without preg-
nancy, and concluded that G-CSF have a key role in the
pregnancy achievement /maintenance [29]. And another
study by Rahmati et al. demonstrated that infertile women
with RIF have a significantly lower level of G-CSF recep-
tors at the maternal-fetal interface, and G-CSF administra-
tion would be increase the expression of G-CSF receptors
[26]. Local G-CSF administration significantly increased
the expression of CD16, CD56, and LIF, which enhance
the chance of pregnancy [18]. One study showed an
improved implantation and pregnancy rates, and believed
that local infusion of G-CSF was both chemical stimula-
tion and mechanical stimulation, which lead to the secre-
tion of endogenous cytokines and the activation of the
endocrine paracrine pathways [18].
Thirdly, G-CSF might affect reproduction, implantation,
and pregnancy through several possible mechanisms.
G-CSF has been shown to induce the trophoblasts prolif-
eration, invasion and maintenance during pregnancy [30,
31]. G-CSF also plays a key role during the embryo im-
plantation process. G-CSF was involved in modulating
genes, which were associated with adhesion of embryo,
cell migration, tissue remodeling and angiogenesis. All of
these processes are necessary for embryo implantation
and placentation [26].
Lastly, successful pregnancy can be seen as an immune
challenge to the maternal because the embryo was semi-
allogenic. G-CSF might be induce appropriate modifica-
tion which agree the immune tolerance in pregnancy;
G-CSF switches the T cell cytokine secretion profile to
the Th-2 responses, and promotes the differentiation of
dendritic cell and regulatory T cell [42], which are im-
portant parts of the immunoregulatory events that occur
before and after the implantation in the uterus [27].
Whereas some studies failed to find beneficial effect of
G-CSF. We think the possible reasons were: first, the
small sample size, and the less number of cycles. Second,
the relatively low dose of G-CSF administrated. Third,
once time of G-CSF administration. We supposed that
the treatment effect would be obvious if the dose and
the frequency of G-CSF administration were increased.
The ideal route of G-CSF administration has not been
identified yet. Previous studies have used G-CSF via
either subcutaneous injection or intrauterine infusion. In
order to explore which route was better, we evaluated
the effect on outcome with different routes of G-CSF
administration. We found that G-CSF administrated sub-
cutaneously resulted in significantly increased PR [OR 3.12
(95 % CI 1.67–5.81)] and IR [OR 2.82 (95 % CI 1.29–6.15)],
whereas G-CSF administrated via uterine infusion had no
beneficial effect on the PR [OR 1.42 (95 % CI 0.91–2.24)]
and IR [OR 1.10 (95 % CI 0.76–1.60)] after ART. But the
exact reason for this phenomenon is not clear.
As far as the strength, the meta-analysis resulted in a
more accurate estimation with the pooled ORs value
than single study. The pooled results of included studies
indicated that G-CSF administration has a beneficial ef-
fect on pregnancy and implantation after IVF/ICSI/FET
cycles with thin endometrium or RIF. When evaluating
the effect of G-CSF administration on pregnancy, six
studies were included, and the combined OR was above
one with 95 % CI 1.19–3.46. While evaluating the effect
of G-CSF administration on implantation, the combined
OR showed an increased trend in IR but the difference
had no significances (95 % CI 0.74–3.41).
Besides, there were also some limitations. A major limita-
tion of the present study was the high level of heterogeneity
among these included studies’ characteristics: different
study object (cycle with thin endometrium / RIF), different
treatment types (IVF / ICSI / FET) and different routes
(subcutaneous injection / intrauterine infusion) and dose of
G-CSF administration. Besides, small number of study sub-
jects in the literature and lack of adjustment for meaningful
confounders were all the flaws of the present study. Not-
withstanding these drawbacks, the present systematic
review and meta-analysis provides a valuable summary of
the results of scientific publications so far.
Conclusion
The present meta-analysis and systematic review sug-
gested that G-CSF administration has beneficial effect
on the clinical pregnancy outcome after IVF/ICSI/FET
cycles. In spite of the small number of studies included
and the variable characteristics of these studies, we sug-
gest that administration of G-CSF subcutaneously would
be an optimal treatment for those suffering thin endo-
metrium or RIF. Further cohort studies are required to
explore the mechanisms undergone the effect and inves-
tigate the best route and dose of G-CSF administration.
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Additional file 1: Figure S1. Funnel plot of analysis for the effect of
G-CSF administration on pregnancy rate, showing the results of Eggers to
assess publication bias. (TIF 293 kb)
Additional file 2: Figure S3. Funnel plot of analysis for the effect of G-CSF
administration on pregnancy rate in thin endometrium or RIF cycles, showing
the results of Eggers to assess publication bias. (TIF 346 kb)
Additional file 3: Figure S4. Funnel plot of analysis for the effect of G-CSF
via different administration routes on pregnancy rate, showing the results of
Eggers to assess publication bias. (TIF 364 kb)
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Additional file 4: Figure S5. Funnel plot of analysis for the effect of G-CSF
administration on embryo implantation rate in thin endometrium or RIF cycles,
showing the results of Eggers to assess publication bias. (TIF 338 kb)
Additional file 5: Figure S6. Funnel plot of analysis for the effect of G-CSF
via different administration routes on embryo implantation rate, showing the
results of Eggers to assess publication bias. (TIF 354 kb)
Additional file 6: Figure S2. Funnel plot of analysis for the effect of G-CSF
administration on embryo implantation rate, showing the results of Eggers to
assess publication bias. (TIF 301 kb)
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